Proscia said on Monday that it is partnering with the University of California, San Francisco with the aim of introducing artificial intelligence into the practice of pathology.
Beginning with prostate cancer, the collaboration will aim to validate the clinical efficacy of computational pathology applications for several high-impact pathology subspecialties, Proscia said.